Lv56
1260 积分 2025-04-30 加入
Sample Size and Power Calculations With Win Measures Based on Hierarchical Endpoints
4天前
已完结
A Note on the Sample Size Formula for a Win Ratio Endpoint
9天前
已完结
Sample Size Formula for General Win Ratio Analysis
11天前
已完结
Transformer-based models for predicting cardiovascular risk in Chinese adults: development and validation
27天前
已完结
Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial
1个月前
已完结
Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
1个月前
已完结
The win ratio approach for composite endpoints: practical guidance based on previous experience
1个月前
已完结
[Statistical methods for extremely unbalanced data in genome-wide association study (2)]
2个月前
已完结
The Clone-Censor-Weight Method in Pharmacoepidemiologic Research: Foundations and Methodological Implementation
2个月前
已完结
皖公网安备34019202002308
